Effective-Component Compatibility of Bufei Yishen Formula III Protects Lung Air-Blood Barrier by Regulating the Oxidative Stress: via the Nuclear Factor-E2-Related Factor 2 Pathway
International Journal of Chronic Obstructive Pulmonary Disease · 2025
DOI: 10.2147/copd.s513071 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Kexin Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P.R. China, …. Hauptthemen laut MEDLINE: Oxidative Stress, Pulmonary Disease, Chronic Obstructive, NF-E2-Related Factor 2, Drugs, Chinese Herbal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Sciences Foundation of China.
Abstract (Originalsprache)
Purpose
Bufei Yishen formula (BYF) is an effective treatment strategy for chronic obstructive pulmonary disease (COPD). Effective-component compatibility of BYF III (ECC-BYF III), composed of 5 active ingredients (ginsenoside Rh1, paeonol, astragaloside, icariin and nobiletin) from BYF, has similar effects to BYF in intervening COPD. The abnormal structure and hypofunction of lung air-blood barrier induces inefficiency gas exchange and promotes development of COPD. However, the role of ECC-BYF III in the air-blood barrier remains unknown. This study dedicated to exploring the effect and mechanism of ECC-BYF III improve structure and function of lung air-blood barrier in COPD.
Methods
A COPD rat model was established to study the treatment of ECC-BYF III against COPD. The protective effect of ECC-BYF III on COPD was evaluated through pulmonary function and lung tissue pathology. The structure damage of the lung air-blood barrier was assessed using electron microscopy and immunofluorescence. Finally, we proved the regulating effect of ECC-BYF III in oxidative via the Nrf2 pathway.
Results
The ECC-BYF III could significantly alleviate reduced pulmonary function, decrease damage of lung tissue and regulate oxidative stress in COPD rats. And ECC-BYF III reduced thickness of respiratory membrane, ameliorated damage of pulmonary capillary endothelial cells (PCECs) and alveolar epithelial cells (AECs) in COPD rats. Also, ECC-BYF III protected the function and normal cell morphology of type I alveolar epithelial cell (AT I) and type II alveolar epithelial cell (AT II) in COPD rats. Lastly, ECC-BYF III was indicated to adjust the Nrf2 pathway to improve oxidative stress and protect lung air-blood barrier in COPD rats.
Conclusion
ECC-BYF III protects lung air-blood barrier in COPD by regulating oxidative stress via Nrf2 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P.R. China, Henan University of Chinese Medicine, Zhengzhou, People's Republic of…
- Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.
ORCID-Profile: Yange Tian
Förderung
- National Natural Sciences Foundation of China
Zitieren
APA
Xu, K., Shao, X., Lu, R., Liao, Y., Zhao, Y., Wang, B., Qiu, Z., & Tian, Y. (2025). Effective-Component Compatibility of Bufei Yishen Formula III Protects Lung Air-Blood Barrier by Regulating the Oxidative Stress: via the Nuclear Factor-E2-Related Factor 2 Pathway. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s513071
Vancouver
Xu K, Shao X, Lu R, Liao Y, Zhao Y, Wang B, et al. Effective-Component Compatibility of Bufei Yishen Formula III Protects Lung Air-Blood Barrier by Regulating the Oxidative Stress: via the Nuclear Factor-E2-Related Factor 2 Pathway. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s513071
BibTeX
@article{Xu2025,
author = {Xu, Kexin and Shao, Xuejie and Lu, Ruilong and Liao, Yixi and Zhao, Yakun and Wang, Bo and Qiu, Zhiguang and Tian, Yange},
title = {Effective-Component Compatibility of Bufei Yishen Formula III Protects Lung Air-Blood Barrier by Regulating the Oxidative Stress: via the Nuclear Factor-E2-Related Factor 2 Pathway},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2025},
doi = {10.2147/copd.s513071}
}
EUVIMED